{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:36:10Z","timestamp":1758807370995},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12149-018-1243-2","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T18:43:04Z","timestamp":1519152184000},"page":"372-377","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["FDG-PET\/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)"],"prefix":"10.1007","volume":"32","author":[{"given":"Salvatore","family":"Annunziata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarosa","family":"Cuccaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Tisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hohaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittoria","family":"Rufini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"issue":"4","key":"1243_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/10428194.2016.1213824","volume":"58","author":"I Wong-Sefidan","year":"2017","unstructured":"Wong-Sefidan I, Byrtek M, Zhou X, et al. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice. Leuk Lymphoma. 2017;58(4):809\u201315.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"1243_CR2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/10428194.2016.1196815","volume":"58","author":"L Kostakoglu","year":"2017","unstructured":"Kostakoglu L, Goy A, Martinelli G, et al. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study. Leuk Lymphoma. 2017;58(2):372\u201381.","journal-title":"Leuk Lymphoma"},{"issue":"35","key":"1243_CR3","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30(35):4317\u201322.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1243_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12149-014-0874-1","volume":"28","author":"Z Lu","year":"2014","unstructured":"Lu Z, Lin M, Downe P, et al. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med. 2014;28(8):805\u201311.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"1243_CR5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25(2):442\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"1243_CR6","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1(1):e17\u201327.","journal-title":"Lancet Haematol"},{"issue":"3","key":"1243_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00259-013-2441-8","volume":"41","author":"C Tychyj-Pinel","year":"2014","unstructured":"Tychyj-Pinel C, Ricard F, Fulham M, et al. PET\/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study. Eur J Nucl Med Mol Imaging. 2014;41(3):408\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1243_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00277-015-2553-2","volume":"95","author":"HJ Adams","year":"2016","unstructured":"Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic review. Ann Hematol. 2016;95(1):11\u201318.","journal-title":"Ann Hematol"},{"issue":"12","key":"1243_CR9","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00277-016-2808-6","volume":"95","author":"HJ Adams","year":"2016","unstructured":"Adams HJ, Kwee TC. No convincing evidence to support postinduction FDG-PET in follicular lymphoma. Ann Hematol. 2016;95(12):2085\u20136.","journal-title":"Ann Hematol"},{"issue":"8","key":"1243_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s12149-016-1092-9","volume":"30","author":"S Annunziata","year":"2016","unstructured":"Annunziata S, Cuccaro A, Calcagni ML, et al. Interim FDG-PET\/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30(8):588\u201392.","journal-title":"Ann Nucl Med"},{"key":"1243_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00259-014-2715-9","volume":"41","author":"D Hasenclever","year":"2014","unstructured":"Hasenclever D, Kurch L, Mauz-K\u00f6rholz C, et al. qPET\u2014a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1301\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1243_CR12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s12094-015-1437-1","volume":"17","author":"M Provencio Pulla","year":"2015","unstructured":"Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, et al. SEOM clinical guidelines for the treatment of follicular non-Hodgkin\u2019s lymphoma. Clin Transl Oncol. 2015;17(12):1014\u20139.","journal-title":"Clin Transl Oncol"},{"key":"1243_CR13","first-page":"1123","volume":"41","author":"A Chiaravalloti","year":"2014","unstructured":"Chiaravalloti A, Danieli R, Abbatiello P, et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin\u2019s lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1123\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1243_CR14","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00259-014-2879-3","volume":"41","author":"E Laffon","year":"2014","unstructured":"Laffon E, Marthan R. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology. Eur J Nucl Med Mol Imaging. 2014;41:2154.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1243_CR15","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00259-014-2880-x","volume":"41","author":"D Hasenclever","year":"2014","unstructured":"Hasenclever D, Kurch L, Kluge R. Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan. Eur J Nucl Med Mol Imaging. 2014;41:2155\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1243_CR16","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00259-014-2925-1","volume":"42","author":"E Laffon","year":"2015","unstructured":"Laffon E, de Clermont H, Lamare F, et al. Liver SUV versus stage in Hodgkin\u2019s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging. 2015;42:164\u20135.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1243_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s00259-014-2926-0","volume":"42","author":"A Chiaravalloti","year":"2015","unstructured":"Chiaravalloti A, Schillaci O. Reply to comments by Laffon et al. Liver SUV versus stage in Hodgkin\u2019s lymphoma: the total amount of uptake may play a role in the inverse relationship. Eur J Nucl Med Mol Imaging. 2015;42:166.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1243_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2214\/AJR.10.4923","volume":"195","author":"MC Adams","year":"2010","unstructured":"Adams MC, Turkington TG, Wilson JM, et al. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310\u201320.","journal-title":"AJR Am J Roentgenol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-018-1243-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1243-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-018-1243-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:53:12Z","timestamp":1550623992000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-018-1243-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1243"],"URL":"https:\/\/doi.org\/10.1007\/s12149-018-1243-2","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}